Related Experiment Video
Updated: Mar 5, 2026
Cell-based Flow Cytometry Assay to Measure Cytotoxic Activity
Published on: December 17, 2013
Cytotoxic Antibody Detection by Means of Flow-Cytometric Cross-Match
1Research and Application Center for Scientific and Technological Investigations, Namık Kemal University, Tekirdag, Turkey.
Insights
The novel cytotoxic flow-cytometric cross-match (cFCXM) assay detects complement-mediated cell death and IgG binding simultaneously. This method offers a streamlined approach for histocompatibility testing, potentially reducing laboratory workload.
Area of Science:
- Immunology
- Transplantation Science
- Clinical Chemistry
Background:
- Histocompatibility testing traditionally uses separate complement-dependent lymphocytotoxicity (CDC-XM) and flow-cytometric cross-match (FCXM) assays.
- These methods have fundamental differences in evaluating donor-recipient compatibility.
- A novel assay, cytotoxic flow-cytometric cross-match (cFCXM), has been developed to potentially overcome limitations of existing techniques.
Purpose of the Study:
- To evaluate the performance and limits of the cFCXM technique.
- To assess its ability to detect complement-dependent cell death and IgG binding.
- To compare cFCXM with established CDC-XM and FCXM methods.
Main Methods:
- Standard CDC-XM, FCXM, and cFCXM tests were performed.
- Commercially available positive and negative serum samples were used.
- Lymphocytes from healthy donors were utilized for the assays.
Main Results:
- cFCXM successfully detected complement-dependent cell death, with ratios comparable to CDC-XM.
- The assay enabled simultaneous detection of both complement-dependent cell death and IgG binding.
- At higher positive serum concentrations, cFCXM showed lower IgG-FITC MFI values compared to conventional FCXM, particularly for dead cells.
Conclusions:
- The cFCXM technique effectively detects complement-mediated cell death and IgG binding in a single assay.
- This combined detection capability may significantly reduce bench time and overall laboratory workload.
- cFCXM presents a promising alternative for histocompatibility testing in transplantation.
Background:
Complement-dependent lymphocytotoxicity (CDC-XM) and flow-cytometric (FCXM) cross-match are analyzed individually for each donor and recipient pair, because these techniques have fundamental differences for the evaluation of histocompatibility. Lately, cytotoxic flow-cytometric cross-match (cFCXM) has been developed as an alternative to both CDC-XM and FCXM techniques. We evaluated the limits of cFCXM with the use of different positive serum dilutions.
Methods:
CDC-XM, FCXM, and cFCXM tests were performed with the use of commercially available negative and positive serum samples and lymphocytes from healthy donors.
Results:
Complement-dependent cell death was successfully detected with the use of cFCXM. Complement-dependent cell death ratios in cFCXM were similar those in CDC-XM. With cFCXM, not only complement-dependent cell death but also IgG binding could be detected within a single assay. At higher concentrations of the positive serum, IgG-fluorescein isothiocyanate (FITC) mean fluorescent intensity (MFI) values detected with the use of cFCXM were less than those of conventional FCXM. Correspondingly, for dead cells, MFI values of IgG-FITC were less than those of live cells in higher positive serum concentrations in the cFCXM assay. Moreover, our results demonstrated that in cFCXM analysis, the decreasing ratio of dead cells at increasing positive serum dilutions was not in parallel with the same decrease in IgG-FITC MFI values.
Conclusions:
The cFCXM technique detects complement-mediated cytotoxic cell death with the additional ability to show IgG binding in the same tube and therefore may reduce the necessary bench time and workload.
